Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
repeated dose toxicity: oral
Adequacy of study:
other information

Data source

Reference
Reference Type:
other: Body responsible for the test
Title:
Unnamed

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
other: 96/54/EG, B.7; OECD 407 (1995)
GLP compliance:
yes
Limit test:
no

Test animals

Species:
other: rat, Wistar Hsd Cpb:WU

Administration / exposure

Route of administration:
oral: unspecified
Vehicle:
other: 2 % aqueous Cremophor EL
Details on oral exposure:
Method of administration:
gavage
Duration of treatment / exposure:
Test duration: 28 days
Frequency of treatment:
Dosing regime: 7 days/week
No. of animals per sex per dose:
Male: 5 animals at 0 mg/kg bw/day
Male: 5 animals at 100 mg/kg bw/day
Male: 5 animals at 500 mg/kg bw/day
Male: 5 animals at 1000 mg/kg bw/day
Female: 5 animals at 0 mg/kg bw/day
Female: 5 animals at 100 mg/kg bw/day
Female: 5 animals at 500 mg/kg bw/day
Female: 5 animals at 1000 mg/kg bw/day

Results and discussion

Results of examinations

Details on results:
Clinical observations:
No mortality occurred during the study period.

There were no effects reported in clinical observations
(including open field), body weight development and food
intake.

Detailed behavioural investigation (FOB) showed reduced
number of rearing in males at 1000 mg/kg bw/d, which was
caused by individually low values in 4/5 animals. In

1000 mg/kg bw/d females both mean and individual motor and
locomotor activity were increased compared to control.

Laboratory findings:
Haematology did not reveal toxicologically relevantly
treatment-related changes on parameters on red and white
blood and on blood coagulation.

Clinical biochemistry revealed statistically significant
increase of triglyceride concentrations in males at 500

and 1000 mg/kg bw/d and in females at 1000 mg/kg bw/d.

Total bilirubin was decreased in males and in females
(statistically significant) at 1000 mg/kg bw/d.

Urinalysis revealed increased volumes at 500 mg/kg bw/d

and above in males (not dose-dependent) as well as at

1000 mg/kg bw/d in females.

Effects in organs:
In females the relative liver weights were statistically
significantly increased at 500 mg/kg bw/d and above (up to
11 %) and in males absolute spleen weight at 1000 mg/kg bw/d
(23 %).

Necropsy showed dilation of stomach and cecum in males at
500 and 1000 mg/kg bw/d and dilation of the cecum in one
female at 1000 mg/kg bw/d possibly due to motility
disturbances in the gastrointestinal tract; and deformation
of the liver in one male at 500 mg/kg bw/d and in 3/5 males
at 1000 mg/kg bw/d. Furthermore, discoloured popliteal lymph
nodes were observed in males at 500 and 1000 mg/kg bw/d and
in females at all dose groups.

Microscopy revealed a minimal increase of inflammatory

cells in the gastric mucosa in males and females at 500 and
1000 mg/kg bw/d. This cellular reaction should primary
regarded as an enhanced immunological response of the
gastric mucosa, without adverse impact and a high chance of
reversibility. In the liver, inflammatory infiltration with
portal fibrosis and pigment deposits was seen in 3/5 males
at 1000 mg/kg bw/d. The finding was mostly located under

the liver capsule or at liver edges, leading to constriction
of the liver surface. Therefore, the liver deformation in
these animals is discussed to be of traumatic origin and was
not considered to be related by treatment with the test
substance. The liver deformation in one male at

500 mg/kg bw/d was based on cystic dilation of a hepatic
vein. In females, hepatocellular glycogen deposits were
increased at 1000 mg/kg bw/d. In the testes, spermatic
exfoliation, tubular atrophy and spermatic giant cells were
observed at 500 and 1000 mg/kg bw/d, partly leading to
spermatic debris or oligospermia in the epididymides beyond
500 mg/kg bw/d. In the popliteal nodes, pigment deposits
were found in males beyond 500 mg/kg bw/d, while in females
they occurred in all dose groups. These findings are
supposed to be caused by blood removal from the caudal vein.

Effect levels

open allclose all
Dose descriptor:
NOAEL
Effect level:
100 mg/kg bw/day (nominal)
Basis for effect level:
other: original NCD unit is mg/kg/day.
Dose descriptor:
NOEL
Effect level:
100 mg/kg bw/day (nominal)
Basis for effect level:
other: original NCD unit is mg/kg/day.

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
Classified as: Not classified